These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 24947464

  • 1. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
    Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, Stensbøl TB, Bundgaard C, Arnt J, Kikuchi T.
    J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
    [Abstract] [Full Text] [Related]

  • 2. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
    Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbøl TB, Kikuchi T.
    J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
    [Abstract] [Full Text] [Related]

  • 3. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization.
    Oosterhof CA, El Mansari M, Blier P.
    J Pharmacol Exp Ther; 2014 Dec; 351(3):585-95. PubMed ID: 25225185
    [Abstract] [Full Text] [Related]

  • 4. Involvement of presynaptic 5-HT1A receptors in the low propensity of brexpiprazole to induce extrapyramidal side effects in rats.
    Mombereau C, Arnt J, Mørk A.
    Pharmacol Biochem Behav; 2017 Feb; 153():141-146. PubMed ID: 28057524
    [Abstract] [Full Text] [Related]

  • 5. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors.
    Gogos A, Kwek P, Chavez C, van den Buuse M.
    J Pharmacol Exp Ther; 2010 Apr; 333(1):218-27. PubMed ID: 20042529
    [Abstract] [Full Text] [Related]

  • 6. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Kumagai T, Nakazato A, Nagamine M, Yamaguchi K, Tomisawa K.
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A, Artaiz I, Innerárity A, Del Olmo E, Castro E, Labeaga L, Pazos A, Orjales A.
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [Abstract] [Full Text] [Related]

  • 8. Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5-HT2A receptors in rats.
    Amada N, Akazawa H, Ohgi Y, Maeda K, Sugino H, Kurahashi N, Kikuchi T, Futamura T.
    Neuropsychopharmacol Rep; 2019 Dec; 39(4):279-288. PubMed ID: 31487433
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
    Bardin L, Auclair A, Kleven MS, Prinssen EP, Koek W, Newman-Tancredi A, Depoortère R.
    Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
    [Abstract] [Full Text] [Related]

  • 10. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.
    Depoortere R, Boulay D, Perrault G, Bergis O, Decobert M, Françon D, Jung M, Simiand J, Soubrié P, Scatton B.
    Neuropsychopharmacology; 2003 Nov; 28(11):1889-902. PubMed ID: 12902993
    [Abstract] [Full Text] [Related]

  • 11. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.
    Yoshimi N, Fujita Y, Ohgi Y, Futamura T, Kikuchi T, Hashimoto K.
    Pharmacol Biochem Behav; 2014 Sep; 124():245-9. PubMed ID: 24955861
    [Abstract] [Full Text] [Related]

  • 12. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors.
    Ishima T, Futamura T, Ohgi Y, Yoshimi N, Kikuchi T, Hashimoto K.
    Eur Neuropsychopharmacol; 2015 Apr; 25(4):505-11. PubMed ID: 25687838
    [Abstract] [Full Text] [Related]

  • 13. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator.
    Yoshimi N, Futamura T, Hashimoto K.
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):356-64. PubMed ID: 25600995
    [Abstract] [Full Text] [Related]

  • 14. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA.
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [Abstract] [Full Text] [Related]

  • 15. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
    Assié MB, Ravailhe V, Faucillon V, Newman-Tancredi A.
    J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
    [Abstract] [Full Text] [Related]

  • 16. A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia.
    Girgis RR, Forbes A, Abi-Dargham A, Slifstein M.
    Neuropsychopharmacology; 2020 Apr; 45(5):786-792. PubMed ID: 31847007
    [Abstract] [Full Text] [Related]

  • 17. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
    McCreary AC, Glennon JC, Ashby CR, Meltzer HY, Li Z, Reinders JH, Hesselink MB, Long SK, Herremans AH, van Stuivenberg H, Feenstra RW, Kruse CG.
    Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
    [Abstract] [Full Text] [Related]

  • 18. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
    Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y.
    Eur J Pharmacol; 2007 Oct 31; 572(2-3):160-70. PubMed ID: 17662268
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like effects in rats.
    Jantschak F, Brosda J, Franke RT, Fink H, Möller D, Hübner H, Gmeiner P, Pertz HH.
    J Pharmacol Exp Ther; 2013 Oct 31; 347(1):57-68. PubMed ID: 23863695
    [Abstract] [Full Text] [Related]

  • 20. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y, Horiguchi M, Rajagopal L, Miyauchi M, Meltzer HY.
    Behav Brain Res; 2015 May 15; 285():165-75. PubMed ID: 25448429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.